Next Article in Journal
2-(4-(Fluorosulfonyloxy)phenyl)benzoxazole
Previous Article in Journal
Synthesis and In Silico Drug-Likeness Modeling of 5-FU/ASA Hybrids
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

1-(2,5-Dimethoxy-4-nitrophenyl)piperidine

Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, Penrhyn Road, Kingston upon Thames KT1 2EE, UK
*
Author to whom correspondence should be addressed.
Molbank 2023, 2023(4), M1744; https://doi.org/10.3390/M1744
Submission received: 8 November 2023 / Revised: 21 November 2023 / Accepted: 24 November 2023 / Published: 27 November 2023

Abstract

:
Treatment of the non-purified mixture of dinitro isomers obtained from the nitration of 1,4-dimethoxybenzene with piperidine led to the isolation of novel but minor adduct, 1-(2,5-dimethoxy-4-nitrophenyl)piperidine (2b) in 15% yield. Yields of nucleophilic aromatic substitution adducts are high when using purified 1,4-dimethoxy-2,5-dinitrobenzene (1b) with piperidine and pyrrolidine to give (2b) and 1-(2,5-dimethoxy-4-nitrophenyl)pyrrolidine (3b) in 76% and 82% yield, respectively.

Graphical Abstract

1. Introduction

1,4-Dimethoxy-2,3-dintrobenzene (1a) is a precursor for the synthesis of potent bioreductive anti-cancer agents [1], the benzimidazole-4,7-diones [2,3] and ring-fused benzimidazolequinones [4,5]. For example, pyrido[1,2-a]benzimidazolequinone (Figure 1), which is 300 times more cytotoxic than the clinical anti-tumor drug mitomycin C under hypoxic conditions, associated with solid tumors [4].
The nitration of 1,4-dimethoxybenzene gives 2,3-dinitrobenzene (1a) as the major product, with isomeric 1,4-dimethoxy-2,5-dinitrobenzene (1b) separated with column chromatography [7] or recrystallization [8].

2. Results and Discussion

To expediate the synthesis of pyrido[1,2-a]benzimidazolequinone (Figure 1) [6], the non-purified mixture of dinitro isomers (1a) and (1b) from the nitration of 1,4-dimethoxybenzene was subjected to heating in piperidine under reflux, giving 1-(3,6-dimethoxy-2-nitrophenyl)piperidine (2a) and 1-(2,5-dimethoxy-4-nitrophenyl)piperidine (2b) in 43% and 15% yield, respectively (Scheme 1).
The NMR spectra show distinct differences in the aromatic region for isomers (2a) and (2b). The para-arrangement of the piperidinyl- and nitro-substituents of 2b gives well-separated singlets (at 6.48 and 7.55 ppm for H-6 and H-3, respectively, Figure 2b), in comparison to the two aromatic doublets (at 6.72 and 6.84 ppm, J = 9.1 Hz, of 4,5-H) in the 1H NMR spectrum of (2a) (Figure 2a [6]).
Given that nucleophilic aromatic substitution adducts of 2,5-dintrobenzene (1b) are novel (see below), column chromatography was used to separate (1b) (11%) on a gram scale from major isomer 1a (54%) after nitration of 1,4-dimethoxybenzene (Scheme 2). Heating purified (1b) in piperidine at reflux gave 1-(2,5-dimethoxy-4-nitrophenyl)piperidine (2b) in 76% yield, with the analogous reaction with pyrrolidine giving 1-(2,5-dimethoxy-4-nitrophenyl)pyrrolidine (3b) in 82% yield. The pyrrolidine adduct (3b) was isolated without a requirement for purification (chromatography or recrystallization), with only evaporation of the reaction mixture carried out after EtOAc-brine extraction. There are no literature data available for adducts (2b) and (3b), thus the compounds are assumed to be new, although (3b) is listed in the catalogues of two Chinese suppliers [9,10].

3. Materials and Methods

3.1. Materials and Measurements

All chemicals were sourced from commercial suppliers and used without purification, including piperidine (99%, ThermoFisherScientific) and pyrrolidine (98%, TCI). Nitric acid (69%, EMSURE®, Merck) and 1,4-dimethoxybenzene (9.95 g, 72.0 mmol, ReagentPlus® 99%, Sigma-Aldrich) gave the mixture of dinitro-isomers (11.67 g, 71%, ratio in Scheme 1), according to this literature procedure [8]. Thin layer chromatography (TLC) was performed on Merck TLC silica gel 60 F254 plates using a UV lamp (254 nm) for visualization. Flash chromatography and dry column vacuum chromatography (DCVC) were performed using Fluka silica gel 60 (particle size 35–70 µm) and Milipore silica gel 60 (particle size 15–40 µm), respectively, using gradient elution of EtOAc (Fischer Scientific, ≥99%) and hexanes (Fischer Scientific, bp 40–60 °C), as eluent. The organic extract was dried using MgSO4 (anhydrous, Fisher Scientific, Extra Pure). Melting point was measured with a Stuart Scientific melting point apparatus, SMP3. Infrared spectrum (IR) was recorded on the solid samples using a Perkin-Elmer Spec 1 with ATR attached, where s, m, and w are strong, medium, and weak signals, respectively. All NMR spectra were recorded in CDCl3 (Eurisotop®, 99.8% atom D) using a Bruker Avance III 400 MHz spectrometer equipped with a 5 mm BBFO+ broadband autotune probe and controlled with TopSpin 3.5.7 acquisition software and IconNMR 5.0.7 automation software Copyright © 2017 Bruker BioSpin GmbH. Chemical shifts are in ppm relative to tetramethylsilane (TMS). 13C NMR spectra were acquired at 100 MHz with complete proton decoupling. NMR assignments are supported by DEPT-135, 1H−1H COSY, and 1H−13C edited HSCQ correlation. HRMS spectra of compounds (2b) and (3b) were obtained at the National Mass Spectrometry Facility at Swansea University using a Waters Xevo G2-S mass spectrometer with an Atmospheric Solids Analysis Probe (ASAP). The precision of all accurate mass measurements was better than 5 ppm.

3.2. Synthesis of 1-(2,5-Dimethoxy-4-nitrophenyl)piperidine (2b)

The mixture of 2,3-dintrobenzene (1a) and 2,5-dintrobenzene (1b) (82:18% ratio by 1H NMR, 0.800 g, 3.5 mmol) and piperidine (1.38 mL, 14.0 mmol) was stirred at reflux for 2 h. EtOAc (20 mL) was added to the cooled red residue, which was washed with brine (3 × 30 mL). The organic layer was dried (MgSO4) and evaporated to dryness. The residue was purified using DCVC with gradient elution of EtOAc/hexane to give 1-(3,6-dimethoxy-2-nitrophenyl)piperidine (2a [6]) (0.400 g, 43%), as a yellow solid, Rf 0.51 (3:7 EtOAc : hexane); and the title compound (2b) (0.140 g, 15%) as a yellow solid; mp 126–127 °C; Rf 0.30 (3:7 EtOAc:hexane); νmax (neat, cm−1) 2929 (m), 2853 (w), 1610 (m), 1571 (m), 1509 (s), 1444 (m), 1312 (s), 1266 (s), 1243 (s), 1210 (s); δH (400 MHz, CDCl3) 1.62–1.65 (m, 2H, 3′-CH2), 1.72–1.78 (m, 4H, 2′-CH2), 3.19 (t, 4H, J = 5.4 Hz, 1′-CH2), 3.87 (s, 3H, 2-CH3), 3.94 (s, 3H, 5-CH3), 6.48 (s, 1H, 6-H), 7.55 (s, 1H, 3-H); δC (100 MHz, CDCl3) 24.2 (3′-CH2), 25.9 (2′-CH2), 51.4 (1′-CH2), 56.2 (CH3), 56.9 (CH3), 103.0 (6-CH), 109.3 (3-CH), 130.7, 144.8, 149.3, 150.5 (all C); HRMS (API+) m/z [M + H]+, C13H19N2O4 calcd. 267.1345, observed 267.1345.
Alternatively, 2,5-Dinitrobenzene (1b) (0.200 g, 0.9 mmol) and piperidine (0.35 mL, 3.6 mmol) were stirred at reflux for 2 h. EtOAc (20 mL) was added to the cooled red residue, which was washed with brine (3 × 30 mL). The organic layer was dried (MgSO4) and evaporated to dryness. The residue was purified using DCVC with gradient elution of EtOAc/hexane to give the title compound (2b) (0.182 g, 76%) as a yellow solid (spectroscopic data identical to above).

3.3. Synthesis of 1-(2,5-Dimethoxy-4-nitrophenyl)pyrrolidine (3b)

2,5-Dinitrobenzene (1b) (0.286 g, 1.3 mmol) and pyrrolidine (0.42 mL, 5.0 mmol) were stirred at reflux for 2 h. EtOAc (20 mL) was added to the cooled brown residue, which was washed with brine (3 × 30 mL). The organic layer was dried (MgSO4) and evaporated to dryness to give the title compound (3b) (0.268 g, 82%), as an orange solid; mp 104–106 °C; Rf 0.45 (2:3 EtOAc:hexane); νmax (neat, cm−1) 2966 (w), 1608 (m), 1565 (m), 1526 (s), 1482 (m), 1450 (m), 1367 (w), 1287 (s), 1268 (s), 1218 (s); δH (400 MHz, CDCl3) 1.91–1.95 (m, 4H, 2′-CH2), 3.54–3.57 (m, 4H, 1′-CH2), 3.74 (s, 3H, CH3), 3.89 (s, 3H, CH3), 5.96 (s, 1H, 6-H), 7.53 (s, 1H, 3-H); δC (100 MHz, CDCl3) 25.5 (2′-CH2), 50.8 (1′-CH2), 56.6 (2 x CH3), 97.1 (6-CH), 110.2 (3-CH), 126.1, 141.3, 146.1, 152.4 (all C); HRMS (API+) m/z [M + H]+, C12H17N2O4 calcd. 253.1188, observed 253.1187.

Supplementary Materials

IR, 1H, 13C NMR spectra and HRMS for compounds (2b) and (3b), and 2D NMR correlation spectra for (2b).

Author Contributions

Methodology: T.M.S., M.R.A.-S., I.B. and M.M. Conceptualization, supervision, writing—review and editing: F.A. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

Data are contained within the article and Supplementary Materials.

Acknowledgments

This manuscript was completed as part of the MPharm dissertation of T.M.S. and MSc dissertations of M.R.A.-S. and I.B. We thank Kingston University for analytical facilities and Swansea University for mass spectra.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Sweeney, M.; Conboy, D.; Mirallai, S.I.; Aldabbagh, F. Advances in the synthesis of ring-fused benzimidazoles and imidazobenzimidazoles. Molecules 2021, 26, 2684. [Google Scholar] [CrossRef] [PubMed]
  2. Gellis, A.; Kovacic, H.; Boufatah, N.; Vanelle, P. Synthesis and cytotoxicity evaluation of some benzimidazole-4,7-diones as bioreductive anticancer agents. Eur. J. Med. Chem. 2008, 43, 1858–1864. [Google Scholar] [CrossRef] [PubMed]
  3. O’Donovan, L.; Carty, M.P.; Aldabbagh, F. First synthesis of N-[(aziridin-2-yl)methyl]benzimidazolequinone and analysis of toxicity towards normal and Fanconi anemia cells. Chem. Commun. 2008, 43, 5592–5594. [Google Scholar] [CrossRef] [PubMed]
  4. Lynch, M.; Hehir, S.; Kavanagh, P.; Leech, D.; O’Shaughnessy, J.; Carty, M.P.; Aldabbagh, F. Synthesis by radical cyclization and cytotoxicity of highly potent bioreductive alicyclic ring fused [1,2-a]benzimidazolequinones. Chem. Eur. J. 2007, 13, 3218–3226. [Google Scholar] [CrossRef] [PubMed]
  5. Moriarty, E.; Carr, M.; Bonham, S.; Carty, M.P.; Aldabbagh, F. Synthesis and toxicity towards normal and cancer cell lines of benzimidazolequinones containing fused aromatic rings and 2-aromatic ring substituents. Eur. J. Med. Chem. 2010, 45, 3762–3769. [Google Scholar] [CrossRef] [PubMed]
  6. Sweeney, M.; Gurry, M.; Keane, L.-A.J.; Aldabbagh, F. Greener synthesis using hydrogen peroxide in ethyl acetate of alicyclic ring-fused benzimidazoles and anti-tumour benzimidazolequinones. Tetrahedron Lett. 2017, 58, 3565–3567. [Google Scholar] [CrossRef]
  7. Shopsowitz, K.; Lelj, J.; MacLachlan, M.J. Regioselectivity in the nitration of dialkoxybenzenes. J. Org. Chem. 2011, 76, 1285–1294. [Google Scholar] [CrossRef] [PubMed]
  8. Hammershøj, P.; Reenberg, T.K.; Pittelkow, M.; Nielsen, C.B.; Hammerich, O.; Christensen, J.B. Synthesis and properties of 2,3-dialkynyl-1,4-benzoquinones. Eur. J. Org. Chem. 2006, 2006, 2786–2794. [Google Scholar] [CrossRef]
  9. CAS Registry Number: 71230-77-8, Catalogue Number: CA0784117. Chemieliva Pharmaceutical, Product List, Jiang Bei Chongqing, China. Available online: https://www.chemieliva.com/new_content.html?casno=71230-77-8 (accessed on 16 October 2023).
  10. CAS Registry Number: 71230-77-8, Catalogue Number: PR-518937. Atomax Chemicals, Product List, Shenzhen, Guangdong, China. Available online: http://en.atomaxchem.com/71230-77-8.html (accessed on 16 October 2023).
Figure 1. Pyrido[1,2-a]benzimidazolequinone [4,6].
Figure 1. Pyrido[1,2-a]benzimidazolequinone [4,6].
Molbank 2023 m1744 g001
Scheme 1. Yields of adducts (2a) and (2b) after dry column vacuum chromatography (DCVC).
Scheme 1. Yields of adducts (2a) and (2b) after dry column vacuum chromatography (DCVC).
Molbank 2023 m1744 sch001
Figure 2. 1H NMR spectra of (a) (2a) [6], and (b) novel isomer (2b), also shown in the Supplementary Materials.
Figure 2. 1H NMR spectra of (a) (2a) [6], and (b) novel isomer (2b), also shown in the Supplementary Materials.
Molbank 2023 m1744 g002
Scheme 2. Synthesis 1,4-dimethoxy-2,5-dintrobenzene (1b) and derived novel adducts (2b) and (3b).
Scheme 2. Synthesis 1,4-dimethoxy-2,5-dintrobenzene (1b) and derived novel adducts (2b) and (3b).
Molbank 2023 m1744 sch002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Syeda, T.M.; Al-Shaidi, M.R.; Basri, I.; Merzouk, M.; Aldabbagh, F. 1-(2,5-Dimethoxy-4-nitrophenyl)piperidine. Molbank 2023, 2023, M1744. https://doi.org/10.3390/M1744

AMA Style

Syeda TM, Al-Shaidi MR, Basri I, Merzouk M, Aldabbagh F. 1-(2,5-Dimethoxy-4-nitrophenyl)piperidine. Molbank. 2023; 2023(4):M1744. https://doi.org/10.3390/M1744

Chicago/Turabian Style

Syeda, Tanjia M., Muadh R. Al-Shaidi, Ibtihal Basri, Mahboub Merzouk, and Fawaz Aldabbagh. 2023. "1-(2,5-Dimethoxy-4-nitrophenyl)piperidine" Molbank 2023, no. 4: M1744. https://doi.org/10.3390/M1744

APA Style

Syeda, T. M., Al-Shaidi, M. R., Basri, I., Merzouk, M., & Aldabbagh, F. (2023). 1-(2,5-Dimethoxy-4-nitrophenyl)piperidine. Molbank, 2023(4), M1744. https://doi.org/10.3390/M1744

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop